Description
Created On: 2020-07-15
Record Count: 3
Primary Industries
- Drugs
- Pain
- Disease
- Migraine
- Therapeutic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 279382
The patents include, but are not limited to Excitatory amino acid receptor antagonists, and, Process for preparing isoquinoline compounds, and, Synthesis of cis-decahydroisoquinoline-3-carboxylic acids.
AMPA/kainate, or AK, antagonist assets including its lead drug candidate, tezampanel, and NGX426.
Tezampanel has a range of effects which may be useful for medicinal purposes, as well as its applications in scientific research. It suppresses both the withdrawal symptoms from morphine and other opioids, and the development of tolerance,as well as having and analgesic effects in its own right. It also has anxiolytic effects in animal studies and has been suggested as a candidate for the treatment of anxiety in humans.
IPSCIO Record ID: 203524
The New Compound shall mean a chemical entity (including salts and solvates thereof, which shall be considered the same New Compound for purposes of this Agreement) covered by any valid and unexpired claim of Licensed Patents, but shall exclude in all cases the Roberts Agreement Compound.
The New Product means a finished, formulated pharmaceutical product containing a New Compound, together with all improvements and line extensions thereon which may be included in any supplement, modification or addition to the relevant Regulatory Approval to the extent that any such improvements or line extensions contain a New Compound.
Licensee is developing alvimopan, a peripherally selective mu opioid antagonist for management of postoperative ileus, opioid induced bowel dysfunction and certain other indications. Alvimopan is in a class of medications called peripherally acting mu-opioid receptor antagonists. It works by protecting the bowel from the constipation effects of opioid (narcotic) medications that are used to treat pain after surgery.
IPSCIO Record ID: 230815
Licensor shall grant a non-exclusive sublicense of Licensors interests and entitlements solely in the Field under another Agreement in the anothers Know-How and the anothers patent Rights relating to the Compounds in the Territory, with the right to grants sublicenses.
Product 220,075 shall mean , the twice daily oral formulation(s} using the Intellectual Property and incorporating the compound 220,075 (bicifadine- analgesic) utilizing the Technologies.
Product 273,547 shall mean the once daily oral formulation using the Intellectual Property and incorporating the compound 273,547 (nonbenzodiazapinen anxiolytic) utilizing the Technologies.
IP relates to a controlled release formulations of bicifadine for the treatment of pain and ocinaplon for the treatment of anxiety disorders and epilepsy.
